The short version of counterion content fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
called the plasticity index that could be used to determine whether contact would be elastic or plastic. The Greenwood-Williamson model requires knowledge of two statistically dependent quantities; the standard deviation of the surface roughness and the curvature of the asperity peaks. An alternative definition of the plasticity index has been given by Mikic. Yield occurs when the pressure is greater than the uniaxial yield stress. Since the yield stress is proportional to the indentation hardness
== Uses in sintering == The sintering process is taking a powder, putting it into a mold and heating it to below its melting point. Sintering is based on atomic diffusion, the atoms in the powder particle diffuse into surrounding particles eventually forming a solid or porous material. It has been discovered that Li2TiO3 powders have a high purity and good sintering ability.
patents, including those for the manufacture of insulin and the manufacture of heparin. He registered his last patent when he was 90 years old. In 1977, on the grounds of Connaught Laboratories Ltd. the Moloney Building opened. Peter J. Moloney and his wife Angela were devout Catholics. They had a daughter and four sons.
Sources: en.wikipedia.org
==== Member of the Order of the British Empire (MBE) ==== Military Commander Steven Andrews, Royal Navy, D257452S. Lieutenant Commander Ross Donald Balfour, Royal Navy, C040712E. Warrant Officer 1 James Adrian Cuthbert, Royal Marines, P047210N. Warrant Officer 1 Engineering Technician (Communication and Information Systems) Steven Gilbertson, Royal Navy, D242982T. Commander Martin John Howard, Royal Navy, C041681L. Lieutenant Commander Alexander Rowan Marsh, Royal Navy, 30033538. Commander Paul O'Dooley, Royal Naval Reserve, C900344D. Chief Petty Officer Engineering Technician (Marine Engineering) Michael John Stephens, Royal Navy, D258366B. Leading Seaman (Diver) Rory Edward Cartwright-Taylor, Royal Navy, 30050838. Lieutenant Sam David Thompson, Royal Navy, 30023663. Commander Roger Simon Wyness, Royal Navy, C037182G. Major John Edward BAILEFF, Royal Regiment of Artillery, 30121479. Major Allan Paul Beard, Intelligence Corps, 25132230. Sergeant Daniel Adam Powderham-Bissell, Intelligence Corps, 25179642. Lieutenant Colonel John George Bradbury, Corps of Royal Electrical and Mechanical Engineers, Army Reserve, 552247. Major (now Acting Lieutenant Colonel) Keith Michael Timothy Brooks, , Royal Regiment of Artillery, Army Reserve, 511819. Captain Barry Lee Byron, , General Service Corps, Army Reserve, 24751476. Captain Giles Alexander Leighton Clarke, The Royal Logistic Corps, 30082571. Major Lisa Jane Clarke, Adjutant General's Corps (Staff and Personnel Support Branch), W0815832. Major James Philip Dott, The Parachute Regiment, 30011021.
Few labs are subject to complaints. For 2024, CLIA budgeted for approximately 209 onsite complaint surveys, representing ~0.06% of the 320,000 CLIA labs. The low volume of lab complaints may be related to complainants' concerns about anonymity and fear of retaliation for filing a complaint. It may be easy for a lab to determine the source of a complaint filed by a lab worker. For example, in some cases, either the nature of the complaint or the piece of testing equipment in question could narrow the list of possible complainants. Because of the difficulty of protecting the anonymity of lab workers who file complaints, whistle-blower protections for such individuals are particularly important. Following congressional testimony by a Maryland hospital lab worker that she and her colleagues feared losing their jobs because of the complaints, a whistleblower protection bill, the "Clinical Laboratory Compliance Improvement Act of 2005", was introduced, but died in committee. CLIA and federal law provide no specific whistleblower protection to laboratory employees who report CLIA violations. However, CLIA complaints made under the False Claims Act (FCA) may be afforded whistleblower protections. The FCA, which prohibits fraud against government programs, including Medicare and Medicaid, may cover CLIA violations that give rise to FCA violations, such as laboratory deficiencies that render billed services medically worthless. Whether CLIA compliance is a condition of Medicare payment is a contested issue.
==== United States ==== In the United States, buprenorphine and buprenorphine with naloxone were approved for opioid use disorder by the Food and Drug Administration in October 2002. The DEA rescheduled buprenorphine from a schedule V drug to a schedule III drug just before approval. The ACSCN for buprenorphine is 9064, and being a schedule III substance, it does not have an annual manufacturing quota imposed by the DEA. The salt in use is hydrochloride, which has a free-base conversion ratio of 0.928. In the years before buprenorphine/naloxone was approved, Reckitt Benckiser had lobbied Congress to help craft the Drug Addiction Treatment Act of 2000, which gave authority to the Secretary of Health and Human Services to grant a waiver to physicians with certain training to prescribe and administer schedule III, IV, or V narcotic drugs for the treatment of addiction or detoxification. Before this law was passed, such treatment was permitted only in clinics designed specifically for drug addiction. The waiver, which can be granted after the completion of an eight-hour course, was required for outpatient treatment of opioid addiction with buprenorphine from 2000 to 2021. Initially, the number of people each approved physician could treat was limited to 10. This was eventually modified to allow approved physicians to treat up to 100 people with buprenorphine for opioid addiction in an outpatient setting. This limit was increased by the Obama administration, raising the number of patients to which doctors can prescribe to 275.
The UK NHS in 2019 listed Humira, Amgevita, Hulio, Hyrimoz, Idacio, and Imraldi as biosimilars available on (almost free) prescription, to be updated in February 2022. The annual cost of adalimumab, the costliest NHS drug, was expected to drop from £400m to £100m by 2021, the biggest saving in NHS history from a single drug negotiation. The best-selling drugs list published by Genetic Engineering & Biotechnology News, shows that Humira occupied the #1 position for 2015 (US$14.012 billion) and 2016 (US$16.078 billion) From 2012 until the US patent expired in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had US$16 billion of global sales. AbbVie reported that Humira achieved US$18.427 billion of sales in 2017. Humira had the largest worldwide drug sales in 2019 and 2020 of US$19.7bn and US$20.4bn respectively.
Sources: en.wikipedia.org
"[...] we commend the Anti-Eugenics Project for their essential work to understand[...] the harmful legacies of eugenicist ideologies. [...] examine the role that philanthropies played in developing and perpetuating eugenics policies and practices. The Rockefeller Foundation is currently reckoning with our own history in relation to eugenics. This requires uncovering the facts and confronting uncomfortable truths, [...] The Rockefeller Foundation is putting equity and inclusion at the center of all our work: [...] confronting the hateful legacies of the past [...] we understand that the work we engage in today does not absolve us of yesterday's mistakes. [...]"
A catch bond is a type of noncovalent bond whose dissociation lifetime increases with tensile force applied to the bond. Normally, bond lifetimes are expected to diminish with force. In the case of catch bonds, the lifetime of the bond actually increases up to a maximum before it decreases like in a normal bond. Catch bonds work in a way that is conceptually similar to that of a Chinese finger trap. While catch bonds are strengthened by an increase in force, the force increase is not necessary for the bond to work. Catch bonds were suspected for many years to play a role in the rolling of leukocytes, being strong enough to roll in presence of high forces caused by high shear stresses, while avoiding getting stuck in capillaries where the fluid flow, and therefore shear stress, is low. The existence of catch bonds was debated for many years until strong evidence of their existence was found in bacteria. Definite proof of their existence came shortly thereafter in leukocytes.
Predator-prey interactions between biofilms and bacterivores, such as the soil-dwelling nematode Caenorhabditis elegans, had been extensively studied. Via the production of sticky matrix and formation of aggregates, Yersinia pestis biofilms can prevent feeding by obstructing the mouth of C. elegans. Moreover, Pseudomonas aeruginosa biofilms can impede the slithering motility of C. elegans, termed as 'quagmire phenotype', resulting in trapping of C. elegans within the biofilms and preventing the exploration of nematodes to feed on susceptible biofilms. This significantly reduced the ability of predator to feed and reproduce, thereby promoting the survival of biofilms. Capsular exopolysaccharides can protect pathogenic bacteria against desiccation and predation, and contribute to their pathogenicity. Sessile bacteria fixed and aggregated in biofilms are less vulnerable compared to drifting planktonic bacteria, as the EPS matrix is able to act as a protective diffusion barrier. The physical and chemical characteristics of bacterial cells can be affected by EPS composition, influencing factors such as cellular recognition, aggregation, and adhesion in their natural environments.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.